首页> 外文期刊>Genetics and Molecular Research >Expression and clinical implications of enhancer of Zeste homolog 2 and p53 protein in squamous cell carcinoma and precancerous lesions in the cervix
【24h】

Expression and clinical implications of enhancer of Zeste homolog 2 and p53 protein in squamous cell carcinoma and precancerous lesions in the cervix

机译:Zeste homolog 2和p53蛋白增强子在宫颈鳞状细胞癌和癌前病变中的表达及其临床意义。

获取原文
           

摘要

We investigated the expression and clinical implications of enhancer of Zeste homolog 2 (EZH2) and p53 protein in cervical squamous cell carcinoma (SCC) and precancerous lesions. EZH2 and p53 expressions in SCC (168), cervical intraepithelial neoplasia (CIN)-I (19), CIN-II (35), and normal tissues (30) were detected by streptavidin-peroxidase-conjugation. The correlation between co-expression of EZH2 and p53 protein and the clinic pathological features and prognosis of SCC were discussed. The positive expression rates of EZH2 and p53 were 6.7, 37.0, and 75.6%, and 3.3, 21.1, and 39.3% in normal cervical tissues, CIN, and SCC, respectively, which were significantly different (P
机译:我们调查了Zeste同系物2(EZH2)和p53蛋白增强子在宫颈鳞状细胞癌(SCC)和癌前病变中的表达及其临床意义。通过链霉亲和素-过氧化物酶-缀合检测到SCC(168),宫颈上皮内瘤样变(CIN)-I(19),CIN-II(35)和正常组织(30)中的EZH2和p53表达。探讨了EZH2和p53蛋白共表达与SCC临床病理特征及预后的关系。 EZH2和p53在正常宫颈组织,CIN和SCC中的阳性表达率分别为6.7%,37.0%和75.6%,3.3%,21.1%和39.3%,差异有统计学意义(P

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号